SciSparc Ltd. Files October 2025 Report (6-K)
Ticker: SPRC · Form: 6-K · Filed: Oct 24, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $700,000, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, agreement, foreign-private-issuer
TL;DR
SciSparc Ltd. filed its October 6-K, detailing a Feb 25 purchase agreement with MitoCareX Bio Ltd.
AI Summary
On February 25, 2025, SciSparc Ltd. entered into a Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd. This filing is a Report of Foreign Private Issuer for the month of October 2025, reporting on this agreement and other company matters.
Why It Matters
This filing provides an update on SciSparc Ltd.'s corporate activities and agreements, including a significant purchase and exchange agreement with MitoCareX Bio Ltd.
Risk Assessment
Risk Level: low — This is a routine filing reporting on past events and general corporate information.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant
- MitoCareX Bio Ltd. (company) — Party to Securities Purchase and Exchange Agreement
- February 25, 2025 (date) — Date of Securities Purchase and Exchange Agreement
- October 2025 (date) — Reporting period for the 6-K
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing serves as a Report of Foreign Private Issuer for the month of October 2025, detailing company activities and agreements.
When did SciSparc Ltd. enter into the Securities Purchase and Exchange Agreement?
SciSparc Ltd. entered into the Securities Purchase and Exchange Agreement on February 25, 2025.
Who is the other party to the Securities Purchase and Exchange Agreement?
The other party to the Securities Purchase and Exchange Agreement is MitoCareX Bio Ltd.
What is SciSparc Ltd.'s principal executive office address?
SciSparc Ltd.'s principal executive offices are located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
Does SciSparc Ltd. file annual reports under Form 20-F or 40-F?
SciSparc Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-10-24 16:00:22
Key Financial Figures
- $700,000 — t N2OFF shall execute a cash payment of $700,000 (the “Cash Consideration”)
- $0.0001 — shares of N2OFF common stock, par value $0.0001 per share (the “Common Stock&rdqu
Filing Documents
- ea0262426-6k_scisparc.htm (6-K) — 15KB
- ea026242601ex99-1_scisparc.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-102142.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SciSparc Ltd. Date: October 24, 2025 By: /s/ Oz Adler Name: Oz Adler Title: Chief Executive Officer and Chief Financial Officer 3